Carlos E. Vigil

Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database

Carlos Vallejos, Henry Gómez, Wilder R. Cruz et al. · Clinical Breast Cancer · 2010 · 164 citations

Medicine, Oncology, Pathology +15

Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model

Kiran Naqvi, Guillermo Garcia‐Manero, Sagar Sardesai et al. · Journal of Clinical Oncology · 2011 · 143 citations

Medicine, Oncology, Clinical Epidemiology +16

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma

SS Mahmood, Samuel Agresta, Carlos E. Vigil et al. · International Journal of Cancer · 2010 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML

Eunice S. Wang, Aaron D. Goldberg, Martin S. Tallman et al. · Journal of Clinical Oncology · 2024 · 44 citations · Full text

Medicine, Oncology, Pharmacology +12

Targeting <i>RARA</i> overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Stéphane de Botton, Thomas Cluzeau, Carlos E. Vigil et al. · Blood Advances · 2022 · 34 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14